PRTA

Prothena Corporation plc (NASDAQ:PRTA) is a late-stage clinical biotechnology company founded in 2012 and headquartered in Dublin, Ireland. The company emerged as a spinoff focused on developing novel protein-based therapies for life-threatening neurodegenerative and rare diseases. Since its founding, Prothena has built a robust pipeline of investigational treatments targeting protein misfolding disorders, including Alzheimer's disease, Parkinson's disease, and various forms of amyloidosis. The company operates through strategic partnerships with major pharmaceutical companies including Roche, Bristol-Myers Squibb, and Novo Nordisk, while maintaining wholly-owned programs that could position it for independent commercialization.